BioVentrix is a privately held
medical device company that manufactures and develops solutions
for the surgical treatment of congestive heart failure, a
disease that affects over 5 million people in the US alone. The
Company’s devices restore a more normal left ventricular shape
through surgical restructuring of the heart’s chamber to the
ideal size.
The Company is transitioning a
successful open surgical technique into a minimally invasive
cardiac catheterization procedure. Taglich Brothers provided
BioVentrix with secured debt financing for the continued
development and commercialization of the next generation of
minimally invasive ventricular restoration techniques.
The information
contained herein does not constitute a solicitation of any order
to buy or sell any securities. The information provided herein
may be displayed and printed for your personal, noncommercial
use only. You may not reproduce, retransmit, distribute,
disseminate, sell, publish, broadcast or circulate the
information to anyone, without the express written consent of
Taglich Brothers, Inc.
